Rhumbline Advisers Grows Position in Atara Biotherapeutics Inc (NASDAQ:ATRA)

Rhumbline Advisers increased its position in shares of Atara Biotherapeutics Inc (NASDAQ:ATRA) by 10.3% in the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 68,067 shares of the biotechnology company’s stock after purchasing an additional 6,332 shares during the period. Rhumbline Advisers’ holdings in Atara Biotherapeutics were worth $961,000 at the end of the most recent quarter.

Several other hedge funds have also recently added to or reduced their stakes in the stock. Zurcher Kantonalbank Zurich Cantonalbank boosted its stake in shares of Atara Biotherapeutics by 59.8% during the 3rd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 2,699 shares of the biotechnology company’s stock worth $38,000 after purchasing an additional 1,010 shares during the period. Oppenheimer & Co. Inc. boosted its stake in shares of Atara Biotherapeutics by 15.2% during the 2nd quarter. Oppenheimer & Co. Inc. now owns 10,132 shares of the biotechnology company’s stock worth $203,000 after purchasing an additional 1,340 shares during the period. Aperio Group LLC purchased a new position in shares of Atara Biotherapeutics during the 2nd quarter worth about $63,000. State Board of Administration of Florida Retirement System boosted its stake in shares of Atara Biotherapeutics by 17.3% during the 2nd quarter. State Board of Administration of Florida Retirement System now owns 22,425 shares of the biotechnology company’s stock worth $451,000 after purchasing an additional 3,310 shares during the period. Finally, Bank of Montreal Can boosted its stake in shares of Atara Biotherapeutics by 81.1% during the 2nd quarter. Bank of Montreal Can now owns 8,314 shares of the biotechnology company’s stock worth $167,000 after purchasing an additional 3,723 shares during the period. 94.95% of the stock is owned by hedge funds and other institutional investors.

A number of equities analysts recently commented on the stock. BidaskClub cut shares of Atara Biotherapeutics from a “hold” rating to a “sell” rating in a research note on Tuesday, October 29th. Mizuho set a $43.00 price target on shares of Atara Biotherapeutics and gave the stock a “buy” rating in a research note on Wednesday, September 18th. ValuEngine raised shares of Atara Biotherapeutics from a “hold” rating to a “buy” rating in a research note on Wednesday, October 2nd. Goldman Sachs Group cut shares of Atara Biotherapeutics from a “neutral” rating to a “sell” rating and dropped their price target for the stock from $14.00 to $9.00 in a research note on Friday, September 27th. Finally, Cowen reiterated a “buy” rating on shares of Atara Biotherapeutics in a report on Friday, September 13th. Two equities research analysts have rated the stock with a sell rating, three have issued a hold rating and nine have issued a buy rating to the stock. The stock currently has a consensus rating of “Buy” and a consensus target price of $28.22.

In related news, insider Joe Newell sold 3,500 shares of the business’s stock in a transaction that occurred on Friday, September 27th. The shares were sold at an average price of $13.51, for a total transaction of $47,285.00. Following the completion of the transaction, the insider now owns 57,998 shares in the company, valued at approximately $783,552.98. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Insiders own 7.00% of the company’s stock.

NASDAQ ATRA opened at $13.19 on Monday. The company has a quick ratio of 9.56, a current ratio of 9.56 and a debt-to-equity ratio of 0.05. The firm has a market cap of $715.06 million, a PE ratio of -2.50 and a beta of 2.04. The company has a 50 day moving average price of $12.92 and a 200 day moving average price of $17.57. Atara Biotherapeutics Inc has a 52 week low of $10.38 and a 52 week high of $43.94.

Atara Biotherapeutics (NASDAQ:ATRA) last posted its quarterly earnings data on Thursday, November 7th. The biotechnology company reported ($1.31) EPS for the quarter, topping the consensus estimate of ($1.40) by $0.09. On average, equities research analysts anticipate that Atara Biotherapeutics Inc will post -5.45 earnings per share for the current fiscal year.

Atara Biotherapeutics Company Profile

Atara Biotherapeutics, Inc, an off-the-shelf T-cell immunotherapy company, develops treatments for patients with cancer, autoimmune, and viral diseases in the United States. It is developing tabelecleucel, a T-cell immunotherapy that is Phase III clinical trials for the treatment of rituximab-refractory epstein-barr virus (EBV) associated post-transplant lymphoproliferative disorder, as well as other EBV associated hematologic and solid tumors, including nasopharyngeal carcinoma.

Recommended Story: Market Indexes

Want to see what other hedge funds are holding ATRA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Atara Biotherapeutics Inc (NASDAQ:ATRA).

Institutional Ownership by Quarter for Atara Biotherapeutics (NASDAQ:ATRA)

Receive News & Ratings for Atara Biotherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Atara Biotherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.